Skip to main content
. 2023 Sep 15;3(9):1862–1874. doi: 10.1158/2767-9764.CRC-23-0087

FIGURE 3.

FIGURE 3

Diagnostic performance of EphA2-NF and CA19-9 for pancreatic cancer in the validation cohort. Dot plots of serum EphA2-NF (A) and CA19-9 (B) in the validation cohort of patients with pancreatic cancer (n = 472), IPMNs (n = 16), and PNETs (n = 19). The cut-off value for EphA2-NF and CA19-9 was defined as 50.0 pg/mL and 37 U/mL, respectively, from the test cohort analysis. Dot plots of EphA2-NF (C) and CA19-9 (D) in pancreatic cancer sera from the validation cohort by stage. E–G, ROC curves of serum EphA2-NF and CA19-9 levels for differentiating pancreatic cancer (left, stage I/II/III/IV), early-stage pancreatic cancer (center, stage I/II), late-stage pancreatic cancer (right, stage III/IV), and HD.